MALT1, which was previously linked to antigen receptor?mediated NF??B activation and lymphomas, is decisive for the expansion of glioblastoma stem?like cells (GSC). © EMBO Journal

French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma. 

© Dr. Edwin P. Ewing, Jr.

Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.

MVX-ONCO-1 Treatment Plan ©MaxiVAX

Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.

A microglial cell, labelled in green, contacts and attacks a myelinated axon (in red). In the presence of the pHERV-W envelope protein, this interaction leads to axonal injury. The blue structures are cell nuclei. ©: HHU / Joel Gruchot / Patrick Küry

Geneva-based GeNeuro SA announced  a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.

John Mattick has been appointed to the Board of Directors of Oxford-based research company Arctoris Ltd.

Micrograph of hepatocellular carcinoma. Liver biopsy. Trichrome stain. © Nephron

Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.

NCI
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m).
© Nattanan Kanchanaprat

GHO Capital raises €975m in largest ever European private equity healthcare fund.
   

BIOCOM AG

Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.

© Zelluna

Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.